beat revenu ep expect even adjust favor non-cor
item numer move part updat full year guidanc larg
line expect subsequ prolong period disappoint
execut perform step right direct challeng persist
arguabl price current valuat pt
revenu report cc beat consensu
forecast estim higher expect blood revenu contribut
beat howev even exclud blood revenu
expect revenu upsid driven breast health cynosur surgic
note preview report beat possibl revenu perform
step right direct subsequ sever quarter disappoint execut
gross margin y/i consensu forecast
oper margin y/i forecast
consensu unfavor mix strong ou higher expect cynosur like
key driver ep expect adjust favor tax rate
share count estim ep slightli expect
revenu increas increas
midpoint bridg fx blood core
revenu guid larg line prior expect
adjust move part consensu head print
note consensu like fulli reflect increment fx headwind
non-rep diagnost royalti payment receiv ultim
put take view updat full year guidanc line expect
ep guid ep guidanc tighten
made progress serv full clear event cyno challeng
remain recent issu fda safeti commun letter monalisa touch
market help novasur remain pressur gener
yet rebuilt confid msd organ revenu growth rate sustain
bright spot arguabl much price
first time sever quarter quarterli execut rel clean
addit surgic show sign recoveri breast health/mdx growth
appear durabl gener also solid share trade
discount peer calendar price-to-earnings basi think cynosur broader
challeng arguabl price rais price target discount
peer price-to-earnings basi also support dcf analysi
pleas see page report import disclosur
believ posit sustain core revenu growth next
sever year even cynosur grow combin
margin expans opportun capit deploy drive ep growth
discount peer yield believ risk/reward favor
tax rate trend downward remain
us tax reform drive tax rate low
high
cynosur growth return
ep growth
cynosur outperform expect
ep growth
return growth
ep growth
develop manufactur supplier premium diagnost medic imag
system surgic product dedic healthcar need women compani
core busi segment focus breast health diagnost gyn surgic
skelet health august acquir gen-prob global leader
develop manufactur market rapid accur cost-effect molecular
diagnost product servic use primarili diagnos human diseas
compani report thomson eikon cowen compani
cowen vs consensu mm except cc fx expect expans base scale back plan d/sg spend ep reiter revenu metric mm except statement mm except per count count forecast streetaccount consensu surgic revenu ahead consensu ahead forecast rel forecast novasur key driver upsid myosur revenu line forecast encouragingli appear novasur declin stabil manag confid surgic growth continu improv streetaccount consensu breast revenu consensu forecast expect beat even better expect mammographi intervent breast solut sale beat expect streetaccount consensu skelet revenu ahead consensu revenu report cc beat consensu forecast estim higher expect blood revenu contribut beat howev even exclud blood revenu beat consensu expect high end guidanc revenu upsid driven breast cynosur surgic note preview report beat possibl revenu perform step right direct subsequ period mix execut gross margin y/i consensu forecast unfavor mix strong ou higher expect cynosur like key driver expens forecast sg expens forecast oper margin y/i forecast consensu rel forecast lower expect expens entir off-set higher expect sg expens lower streetaccount consensu diagnost revenu consensu forecast rel forecast beat entir attribut blood screen mdx cytology/perinat revenu roughli line forecast remain enthus outlook mdx expect virolog materi drive revenu growth beyond streetaccount consensu cynosur revenu line forecast consensu cynosur long way go step right direct rate forecast ep expect adjust favor tax rate share count estim ep slightli expect cowen
compani report thomson eikon cowen compani
cagrcommentstot cc cc fx revenu bridg fx blood total revenu ccmolecular like contribut annual mdx revenueblood blood levelcytolog us mixbreast growth like better initi lsd guidancebreast imag incl breast lsd growth revenu sequenti excl blood royalti grth excl blood breast normal deal excl blood royalti grth excl blood breast excl blood royalti cyno inorgan grth excl blood grth excl blood breast cowen
compani report thomson eikon cowen compani
except per share cc cc fx revenu bridg fx blood corecompar organ expect expans base blood screen headwind fy gross scale back plan d/sg spend gener scale back plan d/sg spend oper scale back plan d/sg spend non-oper interest net non-oper expens materi higher y/yearn tax rate reiter net earn per ep share count except per share gross op consensu cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit cynosur much wors
current model headwind growth novasur pap test
reform stall dc enter agreement larg refer
laboratori maintain busi import mdx franchis
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc juli et dissemin august et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
